Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials

Date

09 Oct 2016

Session

Poster display

Presenters

Caroline Robert

Citation

Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379

Authors

C. Robert1, D. Schadendorf2, G.V. Long3, D. Stroyakovskiy4, E. Levchenko5, V. Chiarion-Sileni6, K. Flaherty7, P. Nathan8, A. Ribas9, M. Davies10, J. Zhang11, L. Chen11, B. Mookerjee12, S. Redhu11, J.J. Grob13

Author affiliations

  • 1 Dermatology, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 2 Department Of Dermatology, University Hospital Essen, 45147 - Essen/DE
  • 3 Melanoma, Melanoma Institute of Australia and The University of Sydney, 2006 - Sydney/AU
  • 4 Chemotherapy Department, Moscow City Oncology Hospital No. 62, Moscow/RU
  • 5 Oncology, N. N. Petrov Research Institute of Oncology, St-Petersburg/RU
  • 6 Melanoma And Skin Cancer Unit, Veneto Oncology Institute, Padova/IT
  • 7 Melanoma, Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, 02114 - Boston/US
  • 8 Department Of Medical Oncology, Mount Vernon Cancer Centre, HA6 2RN - Northwood/GB
  • 9 Medicine, Hematology & Oncology, UCLA Jonsson Comprehensive Cancer Center, 90095 - Los Angeles/US
  • 10 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 11 Global Oncology, Novartis Pharmaceuticals Corporation, East Hanover/US
  • 12 Global Oncology, Novartis Pharmaceuticals Corporation, 07936 - East Hanover/US
  • 13 Service De Dermatologie Et Cancérologie Cutanée, Aix Marseille University, 13885 Marseille CEDEX 05 - Marseille/FR
More

Resources

Background

Dabrafenib (D) + trametinib (T) improved efficacy and better maintained health-related quality of life (HRQOL) vs BRAF inhibitor monotherapy in 2 phase 3 trials of pts with BRAF V600–mutant metastatic melanoma, COMBI-d (D + T vs D + placebo) and COMBI-v (D + T vs vemurafenib). Here, we examine the association of tumor response with HRQOL and symptom scores in COMBI-d and COMBI-v.

Methods

COMBI-d and COMBI-v are randomized, double-blind phase 3 trials in pts with unresectable BRAF V600–mutant metastatic melanoma. The EORTC QLQ-C30 was used to assess HRQOL and symptom scores at baseline and during treatment. Treatment arms in each study were pooled and analyzed by best response (complete response [CR]/partial response [PR] vs stable disease [SD]/progressive disease [PD]). Maximum improvement (MI) was defined as maximum increase from baseline in functional domains and maximum decrease in symptom scores. P values were calculated by 2-sample t test.

Results

In COMBI-d (N = 423; CR/PR, n = 256; SD/PD, n = 148) and COMBI-v (N = 704; CR/PR, n = 417; SD/PD, n = 250), completion rates allowed mean MI scores to be calculated for ≥ 90% of pts. In COMBI-d, pts with CR/PR had greater mean MI in HRQOL vs pts with SD/PD in the global health dimension (13.8 vs 7.5; P = .004) and all functional domains (role [10.2 vs 7.9; P = .425]; social [10.3 vs 6.2; P = .112]; emotional [15.4 vs 10.3; P = .018]; physical [6.0 vs 5.3; P = .664]; cognitive [4.9 vs 1.9; P = .070]). Pts with CR/PR also had greater MI in most symptom scores vs pts with SD/PD, including > 5-point improvements in pain (P = .034) and insomnia (P = .065). Similarly, in COMBI-v, pts with CR/PR had a greater mean MI vs pts with SD/PD in the global health dimension (12.9 vs 7.1; P = .001) and all functional domains (role [9.7 vs 8.3; P = .548]; social [10.1 vs 6.8; P = .134]; emotional [16.1 vs 10.3; P 

Conclusions

Pts with a response had a greater MI from baseline in HRQOL and symptom scores vs pts without a response, demonstrating the association between tumor shrinkage and HRQOL in COMBI-d and COMBI-v.

Clinical trial identification

NCT01597908; first received by clinicaltrials.gov on May 10, 2012 and NCT01584648; first received by clinicaltrials.gov on April 23, 2012

Legal entity responsible for the study

Supported by GlaxoSmithKline. Dabrafenib and trametinib are assets of Novartis AG as of 2 March 2015.

Funding

Supported by GlaxoSmithKline. Dabrafenib and trametinib are assets of Novartis AG as of 2 March 2015.

Disclosure

C. Robert: Consultancy: Novartis, Amgen, BMS, Merck, Roche Honoraria: Novartis, Amgen, BMS, Merck, Roche. D. Schadendorf: Consultancy, Honoraria, Speakers Bureau: Amgen, Novartis, Roche, BMS, MSD Merck, Pfizer Research Funding: BMS, MSD Merck Membership-Advisory Committee: Amgen, Novartis, Roche, BMS, MSD Merck, Pfizer, Array. G.V. Long: Consultancy: Roche, BMS, Merck, Amgen, Novartis Honoraria: BMS, Merck, Novartis. V. Chiarion-Sileni: Consultancy: Novartis, BMS Speakers Bureau: GSK, Novartis Membership on Board of Directors or Advisory Committee: GSK, Novartis, Roche, BMS, MSD. K. Flaherty: Consultancy: Novartis, Roche, Array, Lilly, Takeda Research Funding: Novartis. P. Nathan: Consultancy: Novartis Speakers Bureau: Novartis Membership on Board of Directors or Advisory Committee: Novartis. A. Ribas: Consultancy: Novartis, Merck, Pfizer, Roche Equity Ownership: Kite Pharma Honoraria: Novartis. M. Davies: Research Funding: Genentech/Roche, GSK, AstraZeneca, Sanofi-Aventis, Merck Membership on Board of Directors or Advisory Committee: Novartis, Genentech/Roche, GSK, Sanofi-Aventis, Vaccinex. J. Zhang: Employment: Novartis Equity Ownership: Stockholder. L. Chen: Employment: Novartis Equity Ownership: Novartis. B. Mookerjee: Employment: Novartis Equity Ownership: Novartis, GSK, Incyte, AstraZeneca. S. Redhu: Employment: Novartis. J.J. Grob: Consultancy: Novartis, GSK, Roche, Merck, BMS, Amgen. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings